[
    [
        {
            "time": "",
            "original_text": "医药生物行业:三季报业绩稳健,关注低估值及龙头绩优股",
            "features": {
                "keywords": [
                    "医药生物",
                    "三季报",
                    "业绩稳健",
                    "低估值",
                    "龙头绩优股"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业:三季报业绩稳健,关注低估值及龙头绩优股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11",
            "original_text": "医药行业2018年11月投资策略报告:一阳来复,否极泰来",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "一阳来复",
                    "否极泰来"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2018年11月投资策略报告:一阳来复,否极泰来",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 3,
                "Headline_Structure": 9,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业专题报告:收入整体稳健,Q3扣非净利润增速放缓,内部分化持续",
            "features": {
                "keywords": [
                    "医药生物",
                    "收入稳健",
                    "Q3扣非净利润",
                    "增速放缓",
                    "内部分化"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业专题报告:收入整体稳健,Q3扣非净利润增速放缓,内部分化持续",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]